Pharmaceutical Operations
Pharmaceutical OperationsR & DPipeline
| NAME | ORIGINATOR | INDICATION | DEVELOPMENT STATUS |
| CYSTADROPS® | Recordati | Corneal cysteine crystal deposits in patients with cystinosis | Approved in EU in January 2017 |
| FORTACIN™ | Plethora Solutions | Premature ejaculation | Marketing authorization trasferred to Recordati |
| REAGILA® | Gedeon Richter | Schizophrenia | Approved in EU |
| methadone | Treatment of cancer-related pain in cases of resistance or intolerance to opioids | Under review in France | |
| GRASPA® | Erytech | Acute lymphoblastic leukemia (ALL) in patients with first recurrence of Philadelphia chromosome negative ALL Acute myeloid leukemia (AML) in patients >65 unfit for chemotherapy |
Filed in EU Phase II b |
| CARBAGLU® | Recordati | Hyperammonaemia due to NAGS deficiency and to the main organic acidemias | Development of new formulations in EU and USA Pre-filing in the USA for the organic acidemias indication |
| REC 0551 | Recordati/Meyer Hospital (Florence) | Retinopathy of Prematurity (ROP) | Formulation development Phase II in Italy |
| REC 0438 | Recordati/UFPeptides | Overactive bladder in patients with spinal lesions | Proof of concept planning in EU |
| REC 0559 | Recordati/Mime Tech | Neurotrophic keratitis | Formulation development Clinical development planning |
| REC 0545 | Recordati AP-HP | Acute decompensation episodes in MSUD | Formulation development Clinical development planning |